These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28783168)

  • 1. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor.
    Simond AM; Rao T; Zuo D; Zhao JJ; Muller WJ
    Oncogene; 2017 Oct; 36(43):6059-6066. PubMed ID: 28783168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
    Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
    Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
    [No Abstract]   [Full Text] [Related]  

  • 4. [Generation and comparison of two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer].
    Wang QF; Ding H; Liu BR; Zhang K
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):427-33. PubMed ID: 25187457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.
    Utermark T; Rao T; Cheng H; Wang Q; Lee SH; Wang ZC; Iglehart JD; Roberts TM; Muller WJ; Zhao JJ
    Genes Dev; 2012 Jul; 26(14):1573-86. PubMed ID: 22802530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis.
    Schade B; Rao T; Dourdin N; Lesurf R; Hallett M; Cardiff RD; Muller WJ
    J Biol Chem; 2009 Jul; 284(28):19018-26. PubMed ID: 19435886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel syngeneic mouse mammary carcinoma cell lines from aggressive ErbB2/Neu-overexpressing/PTEN-deficient tumors.
    Wang Q; Ding H; Wang H; Li P; Liu B; Zhang K
    Oncol Rep; 2015 Jan; 33(1):179-84. PubMed ID: 25354531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
    Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden.
    Klover PJ; Muller WJ; Robinson GW; Pfeiffer RM; Yamaji D; Hennighausen L
    Neoplasia; 2010 Nov; 12(11):899-905. PubMed ID: 21076615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
    Utermark T; Schmit F; Lee SH; Gao X; Schaffhausen BS; Roberts TM
    J Virol; 2014 Sep; 88(18):10673-9. PubMed ID: 24991009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors.
    Wang Q; Ding H; Liu B; Li SH; Li P; Ge H; Zhang K
    Int J Oncol; 2014 Apr; 44(4):1277-83. PubMed ID: 24452693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
    Hu L; Liang S; Chen H; Lv T; Wu J; Chen D; Wu M; Sun S; Zhang H; You H; Ji H; Zhang Y; Bergholz J; Xiao ZJ
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E3964-E3973. PubMed ID: 28468801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer.
    Simond AM; Bui T; Zuo D; Sanguin-Gendreau V; Rao T; Phillips WA; Cardiff RD; Muller WJ
    Oncogene; 2022 Jun; 41(25):3445-3451. PubMed ID: 35538223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproductive history determines Erbb2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model.
    Ordonez LD; Melchor L; Greenow KR; Kendrick H; Tornillo G; Bradford J; Giles P; Smalley MJ
    Dis Model Mech; 2021 May; 14(5):. PubMed ID: 34003256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
    Thorpe LM; Spangle JM; Ohlson CE; Cheng H; Roberts TM; Cantley LC; Zhao JJ
    Proc Natl Acad Sci U S A; 2017 Jul; 114(27):7095-7100. PubMed ID: 28630349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
    Zhang C; Xu B; Liu P
    Tumour Biol; 2016 Nov; 37(11):14831-14839. PubMed ID: 27639383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.